Amylyx Pharmaceuticals Inc. (AMLX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
43 THORNDIKE STREET CAMBRIDGE, MA 02141 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2024 MRQ | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 371,362 | 346,945 | |||
| Cash and cash equivalents | 170,201 | 62,526 | |||
| Short-term investments | 201,161 | 284,419 | |||
| Receivables | 40,050 | 15,306 | |||
| Inventory, net of allowances, customer advances and progress billings | 38,323 | 9,769 | |||
| Inventory | 38,323 | 9,769 | |||
| Other undisclosed current assets | 14,931 | 10,113 | |||
| Total current assets: | 464,666 | 382,133 | |||
| Noncurrent Assets | |||||
| Inventory, Noncurrent | 44,957 | ||||
| Operating lease, right-of-use asset | 3,725 | 5,524 | |||
| Property, plant and equipment | 2,686 | 2,611 | |||
| Restricted cash and investments | 719 | 719 | |||
| Other noncurrent assets | 701 | 466 | |||
| Total noncurrent assets: | 52,788 | 9,320 | |||
| TOTAL ASSETS: | 517,454 | 391,453 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 79,785 | 22,493 | |||
| Accounts payable | 22,061 | 6,257 | |||
| Accrued liabilities | 57,724 | 16,236 | |||
| Other undisclosed current liabilities | 2,257 | 24,116 | |||
| Total current liabilities: | 82,042 | 46,609 | |||
| Noncurrent Liabilities | |||||
| Liabilities, other than long-term debt | 1,980 | 4,237 | |||
| Operating lease, liability | 1,980 | 4,237 | |||
| Total noncurrent liabilities: | 1,980 | 4,237 | |||
| Total liabilities: | 84,022 | 50,846 | |||
| Equity | |||||
| Equity, attributable to parent | 433,432 | 340,607 | |||
| Common stock | 7 | 7 | |||
| Additional paid in capital | 738,177 | 694,906 | |||
| Accumulated other comprehensive income (loss) | 197 | (86) | |||
| Accumulated deficit | (304,949) | (354,220) | |||
| Total equity: | 433,432 | 340,607 | |||
| TOTAL LIABILITIES AND EQUITY: | 517,454 | 391,453 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Revenues | 380,786 | 22,230 | ||
| Cost of revenue | (25,441) | (2,993) | ||
| Cost of goods and services sold | (25,441) | (2,993) | ||
| Gross profit: | 355,345 | 19,237 | ||
| Operating expenses | (316,543) | (220,578) | ||
| Operating income (loss): | 38,802 | (201,341) | ||
| Nonoperating income | 15,495 | 3,740 | ||
| Investment income, nonoperating | 16,155 | 4,291 | ||
| Income (loss) from continuing operations before income taxes: | 54,297 | (197,601) | ||
| Income tax expense | (5,026) | (774) | ||
| Net income (loss) available to common stockholders, diluted: | 49,271 | (198,375) | ||
Comprehensive Income ($ in thousands)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Net income (loss): | 49,271 | (198,375) | ||
| Comprehensive income (loss): | 49,271 | (198,375) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 283 | (95) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 49,554 | (198,470) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.